Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Rini, Brian I., McDermott, David F., Hammers, Hans, Bro, William, Bukowski, Ronald M., Faba, Bernard, Faba, Jo, Figlin, Robert A., Hutson, Thomas, Jonasch, Eric, Joseph, Richard W., Leibovich, Bradley C., Olencki, Thomas, Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2016
Soggetti:
Position Article and Guidelines
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109802/
https://ncbi.nlm.nih.gov/pubmed/27891227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0180-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi